Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 4/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.33 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18376038 | 0.86 | HTR2A (0.34) | HTR2ASLC6A4KCNH2HTR2CJAK2 | |
| SCHEMBL22646883 | 0.81 | HTR2A (0.37) | HTR2ASLC6A4KCNH2HTR2CJAK2 | |
| SCHEMBL23070821 | 0.79 | SMN1; SMN2 (0.37) | MKNK2DPP9 | |
| SCHEMBL23070820 | 0.79 | SMN1; SMN2 (0.37) | MKNK2DPP9 | |
| SCHEMBL23070818 | 0.79 | SMN1; SMN2 (0.37) | MKNK2DPP9 | |
| SCHEMBL20337804 | 0.78 | MTNR1A (0.42) | MKNK2 | |
| Hydrochloric Acid SCHEMBL31410913 | 0.78 | SMN1; SMN2 (0.36) | MKNK2DPP9 | |
| SCHEMBL20337803 | 0.78 | MTNR1A (0.42) | MKNK2 | |
| SCHEMBL20337805 | 0.78 | MTNR1A (0.42) | MKNK2 | |
| SCHEMBL669891 | 0.78 | CYP2D6 (0.49) | HTR2ASLC6A4KCNH2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295184-A1 | DIARYL MACROCYCLE POLYMORPH | Turning Point Therapeutics, Inc. | 2023-09-21 | — | — | US | disclosed |
| US-20180194777-A1 | DIARYL MACROCYCLE POLYMORPH | Turning Point Therapeutics, Inc. | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194777-A1 | DIARYL MACROCYCLE POLYMORPH | PKD1, CYP7B1, BRCA1 | MCHR1 4010/4885SLC2A1 4236/4885HTR2A 3401/4885 |
| US-20230295184-A1 | DIARYL MACROCYCLE POLYMORPH | PKD1, CYP7B1, BRCA1 | MCHR1 4010/4885SLC2A1 4236/4885HTR2A 3401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.